摘要
目的探讨替格瑞洛治疗非ST段抬高型急性冠脉综合征(NSTE-ACS)患者的临床效果。方法将2017年10月至2019年4月我科室收治的60例NSTE-ACS患者随机分为对照组(氯吡格雷)与观察组(替格瑞洛),各30例。比较两组的临床效果。结果治疗后,两组的ET-1、NT-proBNP水平、血小板聚集率、LVEDD均降低,NO水平、LVEF均升高,且观察组优于对照组(P<0.05)。观察组MACCE发生率低于对照组(P<0.05)。结论替格瑞洛可改善NSTE-ACS患者血管内皮功能和心功能,降低其血小板聚集率及MACCE发生率而不增加出血风险。
Objective To investigate the clinical effect of ticagrelor in the treatment of non ST elevation acute coronary syndrome(NSTE-ACS)patients.Methods A total of 60 NSTE-ACS patients admitted in our department from October 2017 to April 2019 were randomly divided into control group(clopidogrel)and observation group(ticagrelor),with 30 cases in each group.The clinical effects of the two groups were compared.Results After treatment,the ET-1 and NT-proBNP levels,platelet aggregation rate and LVEDD of the two groups decreased,NO level and LVEF increased,and those in the observation group were better than the control group(P<0.05).The incidence of MACCE in the observation group was lower than that in the control group(P<0.05).Conclusion Ticagrelor can improve the vascular endothelial function and cardiac function of NSTE-ACS patients,reduce the platelet aggregation rate and the incidence of MACCE,without increasing the risk of bleeding.
作者
刁桂花
DIAO Gui-hua(Emergency Department,Zhengzhou Longhai Hospital,Zhengzhou 450000,China)
出处
《临床医学研究与实践》
2020年第15期32-33,共2页
Clinical Research and Practice
